Perspective Therapeutics (CATX) AI Stock Analysis

• Market Cap: $162.91M
• Dividend Yield: N/A
• Average Volume (3M): 584.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 138
• Sector: Healthcare
• Sector Strength: 72
• Industry: Medical - Devices
• EPS (TTM): -1.21
• Shares Outstanding: 74,051,840
• 10 Day Avg. Volume: 605,722
• 30 Day Avg. Volume: 584,295
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 139.61
• Price to Cash Flow (P/CF): 12.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.20
• Price Target Upside: 545.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

Perspective Therapeutics' overall score reflects significant financial challenges, including declining revenues and cash flow inefficiencies, despite maintaining a strong balance sheet. Technical indicators suggest a bearish trend, while valuation metrics are unfavorable due to ongoing losses. The positive impact of recent executive changes offers some hope for improved financial management and strategic direction.

Positive Factors

Clinical trial progress

Enrollment in the ongoing Phase I/IIa trial of lead asset Pb-212-VMT-α-NET in SSTR2+ NETs has picked up with a total of 30 patients treated, indicating progress in clinical trials.

Combination therapy effectiveness

The combination of VMT01 and nivolumab is expected to amplify the therapeutic impact.

Financial stability

Perspective Therapeutics ended the year with $227 million in cash, setting a strong financial foundation for future developments.

Negative Factors

Financial management

The annualized cash burn is $80 million, suggesting a need for efficient management of financial resources to sustain operations over the next two years.

Immune response challenges

Off-target expression of MC1R has been reported in monocytes, macrophages, lymphocytes, and neutrophils, potentially dampening the immune response.

Perspective Therapeutics Business Overview & Revenue Model

Company Description

Perspective Therapeutics (CATX) is a biotechnology company focused on developing therapies for cancer treatment. The company operates in the healthcare sector, specifically within the pharmaceutical and biotechnology industries. Its core products include innovative therapeutic solutions aimed at improving the efficacy and safety of cancer treatments through advanced technology and research.

How the Company Makes Money

Perspective Therapeutics makes money primarily through the development and commercialization of its cancer treatment therapies. Their revenue model includes sales of proprietary drugs and therapies, which are the result of extensive research and development efforts. Additionally, the company may enter into strategic partnerships and licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on sales. These partnerships are crucial in expanding the reach and application of their therapies, thus contributing significantly to their earnings.

Perspective Therapeutics Financial Statement Overview

Summary

Perspective Therapeutics faces significant financial challenges, with declining revenues and persistent losses affecting profitability. Despite these issues, the company maintains a strong balance sheet with high equity and low debt, offering financial stability. However, cash flow inefficiencies highlight operational challenges that need addressing to improve overall financial health and performance.

Income Statement

Perspective Therapeutics is experiencing significant revenue decline in the TTM period, with a notable drop from $1,434,000 in 2023 to $337,000. The company has a negative EBIT and EBITDA margin, reflecting operational inefficiencies. The net profit margin is negative due to high net losses, indicating a challenging profitability scenario. Overall, the financial health in terms of income is weak, with a downward trajectory in revenue and profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 84% and low debt levels, resulting in a favorable debt-to-equity ratio of 0.01. This indicates financial stability despite operational losses. However, the return on equity is negative due to net losses, reflecting poor profitability against the sizable equity base.

Cash Flow

Cash flow management is mixed, with a negative operating cash flow indicating operational cash generation issues. Free cash flow is also negative, reflecting high capital expenditures. The operating cash flow to net income ratio is unfavorable, showing inefficiencies in converting profit to cash. However, financing activities have bolstered cash reserves, providing some liquidity.

Breakdown
TTM	Dec 2023	Dec 2022	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
337.00K	1.43M	7.10M	10.79M	10.05M	9.68M
	Gross Profit
337.00K	1.43M	1.63M	4.62M	5.12M	5.12M
	EBIT
-53.71M	-40.94M	-15.18M	-7.39M	-3.44M	-3.48M
	EBITDA
-45.09M	-39.96M	-14.84M	-7.39M	-3.43M	-3.48M
	Net Income Common Stockholders
-63.78M	-46.51M	-14.67M	-7.15M	-3.19M	-3.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.87M	9.24M	43.76M	55.89M	63.83M	2.39M
	Total Assets
11.91M	97.89M	58.09M	64.44M	70.42M	8.70M
	Total Debt
0.00	2.55M	0.00	524.00K	776.00K	1.00M
	Net Debt
-3.20M	-6.69M	-20.99M	-55.37M	-63.05M	-1.39M
	Total Liabilities
2.25M	22.71M	3.45M	3.16M	3.01M	2.98M
	Stockholders Equity
9.66M	75.18M	54.64M	61.28M	67.41M	5.72M
Cash Flow		Free Cash Flow
-40.59M	-37.98M	-12.47M	-7.98M	-3.22M	-3.91M
	Operating Cash Flow
-696.00K	-36.91M	-12.17M	-7.71M	-2.84M	-3.64M
	Investing Cash Flow
-80.42M	24.37M	-57.68M	-284.00K	-410.00K	-287.00K
	Financing Cash Flow
289.39M	785.00K	56.00K	56.00K	64.68M	994.00K

Perspective Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Negative. The current price of 2.2 is below the 20-day moving average (MA) of 2.47, below the 50-day MA of 2.92, and below the 200-day MA of 8.41, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 31.61 is Neutral, neither overbought nor oversold. The STOCH value of 12.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CATX.

Perspective Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	58 Neutral	$6.26B	285.53	12.21%	―	40.80%	100.62%
FRX	57 Neutral	$254.14M	―	21.91%	―	125.38%	99.20%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	17.48%	1.17%
CATX	47 Neutral	$162.91M	―	-19.42%	―	―	―
ADCT	41 Neutral	$147.63M	―	123.38%	―	1.84%	43.40%

Perspective Therapeutics Corporate Events

Perspective Therapeutics Appoints New Chief Financial Officer

Perspective Therapeutics has appointed Juan Graham as the new Chief Financial Officer, succeeding Jonathan Hunt who remains as Chief Accounting Officer. With nearly 25 years of experience in biopharmaceutical financial management, Graham’s expertise is expected to enhance the company’s strategic financial operations and support its growth, particularly as it advances its clinical programs and builds manufacturing infrastructure.